(NASDAQ: AZN) Astrazeneca's forecast annual revenue growth rate of 7.45% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Astrazeneca's revenue in 2024 is $47,611,000,000.On average, 4 Wall Street analysts forecast AZN's revenue for 2024 to be $80,112,421,563,469, with the lowest AZN revenue forecast at $77,998,261,719,089, and the highest AZN revenue forecast at $81,307,579,896,326. On average, 4 Wall Street analysts forecast AZN's revenue for 2025 to be $86,542,886,777,099, with the lowest AZN revenue forecast at $85,036,992,145,209, and the highest AZN revenue forecast at $87,369,080,052,203.
In 2026, AZN is forecast to generate $91,284,976,864,994 in revenue, with the lowest revenue forecast at $88,719,000,420,990 and the highest revenue forecast at $93,171,535,631,975.